Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment-Reference-Cited by-同舟云学术

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Published:2022-07-30 Issue:10 Volume:61 Page:1405-1416
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Perera Vidya^ORCID,Abelian Grigor,Li Danshi,Wang Zhaoqing,Zhang Liping,Lubin Susan,Bello Akintunde,Murthy Bindu

Funder

Bristol Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-022-01150-1.pdf

Reference50 articles.

1. Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018;19(1):67–71. https://doi.org/10.14744/AnatolJCardiol.2017.8256.

2. Kapil N, Datta YH, Alakbarova N, Bershad E, Selim M, Liebeskind DS, et al. Antiplatelet and anticoagulant therapies for prevention of ischemic stroke. Clin Appl Thromb Hemost. 2017;23(4):301–18. https://doi.org/10.1177/1076029616660762.

3. Gurbel PA, Fox KAA, Tantry US, Ten Cate H, Weitz JI. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation. 2019;139(18):2170–85. https://doi.org/10.1161/CIRCULATIONAHA.118.033580.

4. Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: a review. JAMA Cardiol. 2016;1(6):718–30. https://doi.org/10.1001/jamacardio.2016.2049.

5. Faxon DP. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices. Rev Cardiovasc Med. 2005;6(Suppl 4):S3-14.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation;Expert Opinion on Drug Metabolism & Toxicology;2024-09-02

2. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants;Scientific Reports;2024-07-18

3. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome;Expert Opinion on Pharmacotherapy;2024-07-02

4. Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance;Hematology Reports;2024-03-21

5. Milvexian: A Focus on a New Oral Anticoagulant that Targets Factor XIa for Thromboembolism Prophylaxis;Cardiology in Review;2024-02-02